Ticker: IBIO

iBio, Inc. (NYSE: IBIO) is currently navigating substantial operational challenges as it transitions away from its former model as a Contract Development and Manufacturing Organization (CDMO) towards becoming a biotechnology firm focused on AI-driven antibody discovery. The company has steadily i...